KeyCorp Forecasts Strong Price Appreciation for LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group (NASDAQ:LFST) had its target price raised by equities research analysts at KeyCorp from $8.00 to $9.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s price target would indicate a potential upside of 24.31% from the company’s previous close.

A number of other equities analysts also recently issued reports on the company. BTIG Research raised their price objective on LifeStance Health Group from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, February 2nd. BMO Capital Markets began coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 target price for the company. Barclays assumed coverage on shares of LifeStance Health Group in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 price target on the stock. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Finally, Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.67.

LifeStance Health Group Price Performance

LFST stock opened at $7.24 on Thursday. The company has a market capitalization of $2.82 billion, a P/E ratio of 362.18 and a beta of 1.12. The company has a fifty day moving average price of $7.13 and a 200-day moving average price of $6.20. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.02). The company had revenue of $382.20 million during the quarter, compared to analyst estimates of $378.51 million. LifeStance Health Group had a net margin of 0.68% and a return on equity of 0.66%. The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.01) earnings per share. As a group, equities analysts expect that LifeStance Health Group will post -0.18 EPS for the current year.

LifeStance Health Group announced that its Board of Directors has approved a stock repurchase program on Wednesday, February 25th that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the company to buy up to 3.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other LifeStance Health Group news, Director Robert Bessler sold 119,942 shares of LifeStance Health Group stock in a transaction on Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the sale, the director directly owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the transaction, the insider owned 315,610 shares in the company, valued at $2,177,709. This represents a 13.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 270,086 shares of company stock worth $1,891,264 in the last quarter. 3.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LFST. OLD National Bancorp IN acquired a new position in shares of LifeStance Health Group during the third quarter worth approximately $508,000. Squarepoint Ops LLC grew its position in LifeStance Health Group by 259.1% in the 2nd quarter. Squarepoint Ops LLC now owns 1,360,054 shares of the company’s stock valued at $7,031,000 after purchasing an additional 981,349 shares during the period. Loomis Sayles & Co. L P increased its stake in LifeStance Health Group by 4.5% during the 2nd quarter. Loomis Sayles & Co. L P now owns 2,343,028 shares of the company’s stock valued at $12,113,000 after purchasing an additional 100,657 shares in the last quarter. AXQ Capital LP acquired a new position in LifeStance Health Group during the second quarter worth $343,000. Finally, Alberta Investment Management Corp acquired a new position in LifeStance Health Group during the second quarter worth $607,000. 85.50% of the stock is owned by institutional investors and hedge funds.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Board authorizes a $100 million share repurchase (up to ~3.6% of shares), signaling management thinks the stock is undervalued and reducing float. LifeStance to Repurchase $100M
• Positive Sentiment: Multiple firms raised price targets and ratings (UBS to $12, Canaccord to $10, KeyCorp to $9), increasing visible upside and buy-side interest. Analyst Price Target Raises
• Positive Sentiment: Company set 2026 revenue target of $1.615B–$1.655B and highlighted progress on AI and EHR initiatives that can drive scale and margin expansion over time. 2026 Revenue Target & Initiatives
• Neutral Sentiment: Coverage roundup: several analysts reviewed the stock following the quarter; the market reaction depends on whether upgrades translate into sustained buy-side flows. 6 Analysts Assess LFST
• Negative Sentiment: Q4 EPS missed expectations (reported ~$0.03 vs. ~$0.06 expected) despite revenue beating estimates; EPS weakness and still-modest margins remain near-term headwinds. Q4 2025 Earnings Highlights
• Negative Sentiment: Selling stockholders filed a secondary offering of 25M shares (company not raising proceeds), creating potential supply/overhang that can cap near-term upside. Secondary Public Offering

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.